Cargando…

Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease

Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temp...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavedo, Enrica, Grothe, Michel J., Colliot, Olivier, Lista, Simone, Chupin, Marie, Dormont, Didier, Houot, Marion, Lehéricy, Stephane, Teipel, Stefan, Dubois, Bruno, Hampel, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/
https://www.ncbi.nlm.nih.gov/pubmed/28916821
http://dx.doi.org/10.1038/s41598-017-09780-3
_version_ 1783264486450266112
author Cavedo, Enrica
Grothe, Michel J.
Colliot, Olivier
Lista, Simone
Chupin, Marie
Dormont, Didier
Houot, Marion
Lehéricy, Stephane
Teipel, Stefan
Dubois, Bruno
Hampel, Harald
author_facet Cavedo, Enrica
Grothe, Michel J.
Colliot, Olivier
Lista, Simone
Chupin, Marie
Dormont, Didier
Houot, Marion
Lehéricy, Stephane
Teipel, Stefan
Dubois, Bruno
Hampel, Harald
author_sort Cavedo, Enrica
collection PubMed
description Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2).
format Online
Article
Text
id pubmed-5601919
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-56019192017-09-20 Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease Cavedo, Enrica Grothe, Michel J. Colliot, Olivier Lista, Simone Chupin, Marie Dormont, Didier Houot, Marion Lehéricy, Stephane Teipel, Stefan Dubois, Bruno Hampel, Harald Sci Rep Article Acetylcholinesterase inhibitors are approved drugs currently used for the treatment of Alzheimer’s disease (AD) dementia. Basal forebrain cholinergic system (BFCS) atrophy is reported to precede both entorhinal cortex atrophy and memory impairment in AD, challenging the traditional model of the temporal sequence of topographical pathology associated with AD. We studied the effect of one-year Donepezil treatment on the rate of BFCS atrophy in prodromal AD patients using a double-blind, randomized, placebo-controlled trial of Donepezil (10 mg/day). Reduced annual BFCS rates of atrophy were found in the Donepezil group compared to the Placebo treated arm. Secondary analyses on BFCS subregions demonstrated the largest treatment effects in the Nucleus Basalis of Meynert (NbM) and the medial septum/diagonal band (Ch1/2). Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2). Nature Publishing Group UK 2017-09-15 /pmc/articles/PMC5601919/ /pubmed/28916821 http://dx.doi.org/10.1038/s41598-017-09780-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Cavedo, Enrica
Grothe, Michel J.
Colliot, Olivier
Lista, Simone
Chupin, Marie
Dormont, Didier
Houot, Marion
Lehéricy, Stephane
Teipel, Stefan
Dubois, Bruno
Hampel, Harald
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title_full Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title_fullStr Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title_full_unstemmed Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title_short Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer’s disease
title_sort reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601919/
https://www.ncbi.nlm.nih.gov/pubmed/28916821
http://dx.doi.org/10.1038/s41598-017-09780-3
work_keys_str_mv AT cavedoenrica reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT grothemichelj reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT colliotolivier reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT listasimone reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT chupinmarie reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT dormontdidier reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT houotmarion reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT lehericystephane reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT teipelstefan reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT duboisbruno reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT hampelharald reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease
AT reducedbasalforebrainatrophyprogressioninarandomizeddonepeziltrialinprodromalalzheimersdisease